Direct Transdifferentiation of Somatic Cells to Pancreatic Endocrine Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing pancreatic endocrine cells, such as β cells, are complex, unreproducible, inefficient, and time-consuming, making them unsuitable for rapid production needed for regenerative therapies and drug screening.
Innovation Solution
Introducing GLIS family genes or their products and Neurogenin3 genes into somatic cells to directly transdifferentiate them into pancreatic endocrine cells, bypassing the stem cell stage, using viral vectors or mRNA for gene delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If embryonic stem cells or induced pluripotent stem cells are used to produce β cells, then pancreatic endocrine cells can be produced, but the method becomes complicated and time-consuming
Solution Approach 1:
The invention extracts and utilizes only the essential transcription factors (GLIS1 and Ngn3) required for β cell differentiation, removing the need for complex stem cell culture systems and multiple inhibitors. This direct transdifferentiation approach eliminates unnecessary steps while maintaining production reliability.
Solution Approach 2:
The invention introduces GLIS1 and Ngn3 as intermediary transcription factors that directly mediate the transformation of somatic cells into β cells. These intermediaries bypass the need for stem cell stages and complex differentiation protocols, simplifying the overall process.
2Reliability
If embryonic stem cells or induced pluripotent stem cells are used to produce β cells, then pancreatic endocrine cells can be produced, but the production time increases to at least 21-30 days
Solution Approach 1:
The invention performs preliminary action by directly introducing the key transcription factors GLIS1 and Ngn3 into somatic cells, which immediately initiates the β cell differentiation program. This bypasses the lengthy stem cell expansion and differentiation stages, reducing production time significantly.
Solution Approach 2:
The invention skips the intermediate stem cell stages and directly rushes through to β cell production by expressing critical transcription factors. This shortcut eliminates time-consuming steps while maintaining reliable production of functional β cells.
3Reliability
If embryonic stem cells or induced pluripotent stem cells are used to produce β cells, then pancreatic endocrine cells can be produced, but other cells than β cells are also produced reducing efficiency
Solution Approach 1:
The invention applies local quality by specifically inducing β cell differentiation through targeted expression of GLIS1 and Ngn3 in somatic cells. This localized genetic intervention ensures that only the desired β cell lineage is activated, preventing formation of other cell types and improving production efficiency.
Solution Approach 2:
The invention changes the genetic parameters by introducing specific transcription factors (GLIS1 and Ngn3) that alter the cellular differentiation program. This parameter change directs cells specifically toward the β cell lineage, eliminating production of unwanted cell types and enhancing productivity.
Data Source
AI summary
A method for producing pancreatic endocrine cells, the method includingintroducing one or more genes of a GLIS family or one or more gene products thereof and a Neurogenin3 gene or one or more gene products thereof into somatic cells.